scholarly journals DRUG REVIEW OF KUSHAMOOLA CHURNA WITH TANDULODOK IN ASRUGDARA MANAGEMENT

2021 ◽  
Vol 9 (10) ◽  
pp. 2550-2553
Author(s):  
Aarifa Shaikh ◽  
Umesh Lunawat
Keyword(s):  
Side Effects ◽  
Emotional Stress ◽  
Acute Stage ◽  
Menstrual Period ◽  
Pharmacological Properties ◽  
Fertile Period ◽  
Chronic Therapy ◽  
Acute Condition ◽  
Rice Water ◽  
Drug Review

In Ayurveda, menstruation has been described in 3 phases as rajahkala (menstrual period) rutukala (fertile period) and rutuvyatitkal (premenstrual period) & Do’s and Don’ts regarding this has also been explained in detail. Due to so much physical and emotional stress women are suffering from so many menstrual problems, Asrugdara (menorrhagia) is one of them and in Samhitas its causes, Etiopathogenesis, treatment and complications are ex- plained in detail. Menorrhagia is being treated with hormonal combination have so many side effects in acute as well as chronic therapy. Kushamool churna with tandulodak (Rice water) as explained by Bhaishajya Ratnawali treats Asrugdara in 3 days. Due to its pharmacological properties, it breaks down the pathology of Asrugdara in the acute stage. So, we can formulate this combination for the acute condition of menorrhagia. Keywords: Rajahkala, Rutukala, Rutuvyatitkal, Asrugdara, Menorrhagia, Etiopathogenesis.

A Brief Review on the Development of Novel Potentially Active Azetidin-2-ones Against Cancer

2020 ◽  
Vol 24 (5) ◽  
pp. 473-486 ◽  
Author(s):  
Ligia S. da Silveira Pinto ◽  
Thatyana R. Alves Vasconcelos ◽  
Claudia Regina B. Gomes ◽  
Marcus Vinícius N. de Souza
Keyword(s):  
Side Effects ◽  
Anticancer Agents ◽  
Heterocyclic Compounds ◽  
Biological Activities ◽  
Present Review ◽  
Pharmacological Properties ◽  
Important Group ◽  
Wide Range ◽  
Anti Inflammatory

Azetidin-2-ones (β-lactams) and its derivatives are an important group of heterocyclic compounds that exhibit a wide range of pharmacological properties such as antibacterial, anticancer, anti-diabetic, anti-inflammatory and anticonvulsant. Efforts have been made over the years to develop novel congeners with superior biological activities and minimal potential for undesirable side effects. The present review aimed to highlight some recent discoveries (2013-2019) on the development of novel azetidin-2-one-based compounds as potential anticancer agents.

scholarly journals RUDRA PARPATI: AN AYURVEDIC HERBO – MINERAL DRUG REVIEW

2021 ◽  
Vol 9 (8) ◽  
pp. 1819-1823
Author(s):  
Priyanka. B. Patil ◽  
Usha M ◽  
Ravi R Chavan
Keyword(s):  
Mode Of Action ◽  
Medical Literature ◽  
Review Article ◽  
The Internet ◽  
Pharmacological Properties ◽  
Review Articles ◽  
Therapeutic Uses ◽  
The Subject ◽  
Subject Material ◽  
Drug Review

The main objective of this review article is to discuss the therapeutic uses of Rudra Parpati and to discuss the different pharmacological properties and therapeutic uses of isolated constituent drugs of Rudra Parpati. The authentic subject material has been reviewed from Ayurveda and modern medical literature. Different research and review articles were searched in different journals. The subject material has also been searched on the internet. This review is mainly focused on different aspects of herbo mineral Ayurvedic formulation Rudra Parpati. Parpati rasayana is one among Chaturvidha Rasayana Kalpa which is very effective and can be prepared with less effort. In Ayurveda Rudra Parpati is mentioned in the management of Kasa/cough. Though it is popular as only Parpati used in Kharapaka form & having an indication other than Grahani but still an unexplored treasure with unique therapeutic utility. Hence an attempt has been made to address the therapeutic uses of Rudra Parpati and the probable mode of action of its constituent drugs. Keywords: Rudraparpati, Vataja Kasa.

Dibenzepin and Amitriptyline in the Treatment of Depression

1971 ◽  
Vol 118 (546) ◽  
pp. 523-524 ◽  
Author(s):  
M. Y. Ekdawi
Keyword(s):  
Side Effects ◽  
Antidepressant Drug ◽  
Comparative Trial ◽  
Tricyclic Antidepressant ◽  
Pharmacological Properties ◽  
Double Blind ◽  
Depressed Patients ◽  
Treatment Of Depression ◽  
Significant Difference

Dibenzepin hydrochloride is a new tricyclic antidepressant drug with pharmacological properties midway between those of imipramine and amitriptyline. In a double-blind comparative trial, J. M. Fielding (Med. J. Australia, 1969, 1, 614) found no significant difference in the speed of the effect of the two drugs in depressed patients. He reported that side-effects rated subjectively by patients were maximal before starting on the drugs and tended to decrease with time. The following trial was accordingly staged.

scholarly journals In silico evaluation of some 4-(quinolin-2-yl)pyrimidin-2-amine derivatives as potent V600E-BRAF inhibitors with pharmacokinetics ADMET and drug-likeness predictions

2020 ◽  
Vol 6 (1) ◽  
Author(s):  
Abdullahi Bello Umar ◽  
Adamu Uzairu ◽  
Gideon Adamu Shallangwa ◽  
Sani Uba
Keyword(s):  
Molecular Docking ◽  
Side Effects ◽  
Oral Bioavailability ◽  
In Silico ◽  
Braf Inhibitor ◽  
Docking Studies ◽  
Pharmacological Properties ◽  
Braf Inhibitors ◽  
Docking Analysis ◽  
Risk Parameters

Abstract Background The resistance of V600E-BRAF to the vemurafenib and the side effects of the identified inhibitors trigger the research for a novel and more potent anti-melanoma agents. In this study, virtual docking screening along with pharmacokinetics ADMET and drug-likeness predictions were combined to evaluate some 4-(quinolin-2-yl)pyrimidin-2-amine derivatives as potent V600E-BRAF inhibitors. Results Some of the selected compounds exhibited better binding scores and favorable interaction with the V600E-BRAF enzyme. Out of the screened compounds, two most potent (5 and 9) having good Rerank scores (− 128.011 and − 126.258) emerged as effective and potent V600E-BRAF inhibitors that outperformed the FDA-approved V600E-BRAF inhibitor (vemurafenib, − 118.607). Thus, the molecular docking studies revealed that the studied compounds showed competing for inhibition of V600E-BRAF with vemurafenib at the binding site and possessed better pharmacological parameters based on the drug-likeness rules filters for the oral bioavailability, and ADMET risk parameters. Conclusion The docking analysis, drug-likeness rules filters, and ADMET study identified compounds (5 and 9) as the best hits against V600E-BRAF kinase with enhanced pharmacological properties. This recommends that these compounds may be developed as potent anti-melanoma agents.

Clozapine: Serious Adverse Side Effects, Drug Interactions, and Other Complications of Therapy

1996 ◽  
Vol 9 (2) ◽  
pp. 118-129 ◽  
Author(s):  
Deanna M. Guith
Keyword(s):  
Side Effects ◽  
Health Care Professionals ◽  
Elderly Population ◽  
Adverse Reactions ◽  
Psychotic Disorders ◽  
Antipsychotic Agent ◽  
The Elderly ◽  
Pharmacological Properties ◽  
Treatment Resistant ◽  
Clozapine Therapy

Clozapine (Clozaril®, Sandoz, East Hanover, NJ), an atypical antipsychotic agent with pharmacological properties considerably different from standard neuroleptics, has been found to be of great benefit especially to patients with treatment-resistant psychotic disorders. However, it is these unique pharmacological properties that have also been associated with mul tiple side effects ranging from the relatively benign (ie, sialorrhea during sleep, dizziness) to the potentially fatal (ie, agranulocytosis, seizures, and respiratory depression) which have limited its use. These untoward side effects are particularly problematic in the elderly population who often have concomitant medi cal illnesses requiring multiple medication regimens, including psychotropics that may interact with cloza pine (ie, benzodiazepines, cimetidine, fluoxetine). Because even the most benign of side effects has the potential of becoming fatal in certain circumstances if left unaddressed, it is imperative for patients, clinicians, pharmacists, and all health care professionals to be aware of adverse reactions and possible complica tions of clozapine therapy to prevent significant morbidity and mortality. Copyright © 1996 by W.B. Saunders Company

scholarly journals Tolerance of Benznidazole in Treatment of Chagas' Disease in Adults

2010 ◽  
Vol 54 (11) ◽  
pp. 4896-4899 ◽  
Author(s):  
María-Jesús Pinazo ◽  
José Muñoz ◽  
Elizabeth Posada ◽  
Paulo López-Chejade ◽  
Montserrat Gállego ◽  
...  
Keyword(s):  
Public Health ◽  
Side Effects ◽  
Trypanosoma Cruzi ◽  
European Country ◽  
Chagas Disease ◽  
Health Problem ◽  
Public Health Problem ◽  
Acute Stage ◽  
Chronic Stage

ABSTRACT Chagas’ disease is an emerging public health problem in areas where the disease is not endemic. Treatment with benznidazole has shown efficacy in the acute stage of the disease, but its efficacy in the chronic stage remains controversial, and unwanted side effects are more frequent and severe in adults than in children. This study describes the profile of side effects of benznidazole in a cohort of Trypanosoma cruzi-infected patients in a European country.

scholarly journals GOJIHWADI KWATH- A DRUG REVIEW

2021 ◽  
Vol 9 (06) ◽  
pp. 249-258
Author(s):  
Priyanka Panchola ◽  
◽  
Deepshikha A ◽  
G.P Garg ◽  
◽  
...  
Keyword(s):  
Side Effects ◽  
Respiratory Infections ◽  
Chemical Properties ◽  
Anti Inflammatory ◽  
To Come ◽  
Modern Era ◽  
Drug Review ◽  
And Chemical Properties

Gojihwadi Yoga is described in the 20thcentury textbook ‘SiddhayogaSangraha written by AcharyaYadavji Trikamji one of the illustrious of Ayurveda of modern era. It is described in Jwara rog Adhikara. In Ayurveda it is an excellent combination of16 ingredients which have bronchodilators, mucolytic, anti-inflammatory and expectorants properties like, Draksha, Yashtimadhu, Vasa, Kantakari, Mishreya, Maricha etc. are described in the ancient classics of Ayurveda. Many of the others like Unnav, Khatmi, Khubkalam, Jufa and Gulbanafsa are the contributions of Unani system of medicine. The indication of Gojihwadi kwath as per Ayurveda isJwara, Kasa and Pratishyaya. According to the author it is suitable in respiratory infections where sputum is thick and adhesive in nature and difficult to come out. This article reviews Ayurvedic and chemical properties of this combination.It can be used without any side effects.

Long term recombinant interferon alpha treatment in MS with special emphasis to side effects

1996 ◽  
Vol 1 (6) ◽  
pp. 366-371 ◽  
Author(s):  
Luca Durelli ◽  
MR Bongioanni ◽  
B Ferrero ◽  
D Imperiale ◽  
E Verdun ◽  
...  
Keyword(s):  
Side Effects ◽  
Interferon Alpha ◽  
Drug Efficacy ◽  
Fold Increase ◽  
Recombinant Interferon ◽  
Chronic Therapy ◽  
Stopping Treatment ◽  
Enzyme Elevation ◽  
Recombinant Interferon Alpha

Twenty relapsing-remitting (RR) clinically definite MS patients were treated with 9 MIU intramuscular recombinant interferon alpha-2a (rIFNA) (Rof eron-A, Roche) (n=12) or placebo (n=8) every other day for 6 months and followed up for a further 6 months after stopping treatment Numbers of active lesions at MRI and of patients with clinical-MRI signs of disease activity and lymphocyte interferon gamma production, which were decreased during treatment, returned to values similar to baseline and placebos after stopping treatment rIFNA chronic therapy seems therefore needed in order to maintain drug efficacy. Side effect prof ile was monitored, too, for over 1 year in the same 20 patients plus 25 additional RR MS patients. Besides the typical side effects of type 1 interferon therapy (fever, fatigue, depression, lymphopenia, hepatic enzyme elevation), occurrence of serum autoAbs was noted in 30% patients (in 60% antinuclear and in 80% antithyroid autoAbs). In two patients rIFNA treatment was stopped, in one case for antithyroid autoAbs and hypothyroidism, in the other for antinuclear autoAbs and a five-fold increase of ALT. A careful monitoring of serum autoAbs and of signs of thyroid or liver damage must always precede and accompany longterm type 1 IFN therapy.

scholarly journals DARVYADILEHA: A DRUG REVIEW

2021 ◽  
Vol 9 (5) ◽  
pp. 70-78
Author(s):  
Patni Prachi ◽  
◽  
Singh Deepshikha ◽  
Garg G.P ◽  
◽  
...  
Keyword(s):  
Side Effects ◽  
Iron Deficiency ◽  
Key Words ◽  
Iron Deficiency Anemia ◽  
Deficiency Anemia ◽  
Nutritional Anemia ◽  
Drug Review

Darvyadi Leha is a herbo-mineral compositionused in the treatment of Pandu Roga.Pandu Roga can be co-related with iron deficiency anemia (IDA) due to close clinical presentation.This formulation is mentioned in CharakSamhita under PanduRogaPrakran. As nutritional anemia has an immense prevalence all over Indiaand there are many side effects of oral allopathic iron preparations, thereforeAyurvedicherbo-mineral medications such as Darvyadi Leha can be a better alternative for the treatment of IDA.It is a safe and effective formulation with almost no adverse effects.This article reviews Ayurvedic properties of various ingredients of Dravyadi Leha and discusses how combination of all its ingredients makes the drug so effective.The articles were searched from various indexing sites including Scopus, PubMed, google scholar.The key words used were PanduRoga Iron Deficiency Anemia, Ayurveda.

scholarly journals Patiromer Acetate Induced Hypercalcemia: An Unreported Adverse Effect

2019 ◽  
Vol 2019 ◽  
pp. 1-4
Author(s):  
Shreeyukta Bhattarai ◽  
Stephen Pupillo ◽  
Gulshan Man Singh Dangol ◽  
Erdal Sarac
Keyword(s):  
Adverse Effect ◽  
Chronic Kidney Disease ◽  
Clinical Trials ◽  
Side Effects ◽  
Kidney Disease ◽  
Cation Exchange ◽  
Stage Iv ◽  
Theoretical Possibility ◽  
Chronic Therapy

Hyperkalemia, a potential life threating condition, is a commonly encountered problem in chronic kidney disease (CKD) patients. Patiromer acetate, a nonabsorbable cation exchange polymer, is a gastrointestinal agent for chronic therapy in patients with persistent hyperkalemia. Patiromer is generally well tolerated in patients; common side effects are gastrointestinal, such as diarrhea, constipation, flatulence, and vomiting. Hypercalcemia, although a theoretical possibility, has not been reported in any major clinical trials. We present a case of hypercalcemia associated with patiromer acetate used for treatment of hyperkalemia in a stage IV CKD patient. Clinicians should be aware of the possibility of hypercalcemia while taking patiromer.

Sign in / Sign up

Export Citation Format

Share Document